Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)

BACKGROUND: Combination of erlotinib and bevacizumab is a promising regimen in advanced non-squamous non-small-cell lung cancer (NSCLC). We are conducting a single arm phase II trial which aims to evaluate the efficacy and safety of this regime as a second- or third-line chemotherapy. METHODS: Key e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Shiro, Sakamori, Yuichi, Niimi, Miyuki, Hazama, Megumi, Kim, Young H, Yanagihara, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113989/
https://www.ncbi.nlm.nih.gov/pubmed/21569411
http://dx.doi.org/10.1186/1745-6215-12-120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113989/
https://www.ncbi.nlm.nih.gov/pubmed/21569411
http://dx.doi.org/10.1186/1745-6215-12-120

Ejemplares similares